Gilead exercises option to license nurix's irak4 targeted protein degrader development candidate, nx-0479

Foster city, calif. & san francisco--(business wire)--gilead sciences, inc. (nasdaq: gild) and nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that gilead has exercised its option to exclusively license nurix's investigational targeted protein degrader molecule nx‑0479.
NRIX Ratings Summary
NRIX Quant Ranking